个人简介
EducationPh.D. University of TorontoM.D. University of TorontoAcademic and Professional Experience2015-present Adjunct Distinguished Professor, Faculty of Health Sciences, University of Macau2014-2015 Distinguished Professor, Faculty of Health Sciences, University of Macau
研究领域
Immune thrombocytopeniaLeukemia, Myelodysplastic syndromeThombosis, Transfusion medicine
PatentsTransfusion wristband to improve transfusion safety
近期论文
Representative PublicationsGregory Cheng, Mansoor N. Saleh, Claus Marcher, Sandra Vasey, Bhabita Mayer, Manuel Aivado, Michael Arning, Nicole L. Stone, James B. Bussel. Eltrombopag for the Management of Chronic Immune Thrombocytopenia: a 6-month, Randomised, Phase III Study (RAISE). Lancet. 2011 Jan 29;377(9763):393-402.Yunfeng Cheng, Raymond S.M. Wong, Yannie O.Y. Soo, Chung Hin Chui, Fung Yi Lau, Natalie P.H. Chan, Wai Shan Wong, Gregory Cheng. Initial Treatment of Immune Thrombocytopenic Purpura with High-Dose Dexamethasone. NEJM 2003 Aug; 349:831-836.Bussel J. B., Cheng G., Saleh M.N., Psaiia B., Kovaleva L., Meddeb B., Kloczko J., Hassani H., Mayer B., Stone N.L., Arning M., Provan D., Jenkins J.M. Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura. NEJM 2007 Nov; 357: 2237-47.Bussel B J; Provan D; Shamst T; Cheng Gregory; Psaila B; Kovaleva L; Salama A; Jenkins M J; Roychowdhury D; Mayer B; Stone N and Arning M. “Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.” Lancet vol.373 no.9664, pp.641-8. 2009.02.21.Yunfeng Cheng, Gregory Cheng, CH Chui, FY Lau, Paul KS Chan, Margaret HL Ng, Joseph JY Sung, Raymond SM Wong. ABO Blood Group and Human Susceptibility to SARS. JAMA Vol. 293, no. 12:1450-51, 2005 Mar 05.Kok Hon Lung Stanton; Wong Siu Ming Raymond; Gambari Roberto; Kok Hon Lung Stanton; Cheung Filly; Lam Wing Sze; Lau Fung Yi; Cheng Gregory; “In vitro cytotoxicity of (-)-EGCG octaacetate on MDAMB-231 and SKHep-1 human carcinoma cells: a pharmacological consideration on prodrug design.”. International Journal of Molecular Medicine vol.22 no.6, pp.841-845. 2008.12.Cheng, G. Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?. Clinical Investigation 2015,5,3, 287-296.
